Yes, Spravato Requires Direct Medical Supervision
Spravato (esketamine nasal spray) is administered only under direct supervision of a healthcare professional in a certified healthcare setting, such as a doctor's office, clinic, or hospital. Patients self-administer the nasal spray, but a provider must be present to monitor for side effects like sedation, dissociation, and blood pressure increases. Treatment sessions last at least 2 hours, with no driving or operating machinery allowed for the rest of the day.
Why This Supervision Rule Exists
The FDA's Risk Evaluation and Mitigation Strategy (REMS) program mandates this due to risks of serious outcomes, including sedation, dissociation, respiratory depression, and abuse potential. No patient can take Spravato home; it's dispensed only at the certified site.[1][2]
How the Administration Process Works
Patients receive 2-3 sprays per device (28-84 mg doses), supervised by a provider who instructs on technique. Vital signs are checked before, during (at 40 minutes), and after (at 90 minutes or end of 2 hours). If stable, patients are released; otherwise, monitoring continues.[1][3]
What Happens After a Session
Patients need a designated adult to drive them home and stay for the night. They cannot engage in hazardous activities for 24 hours. Follow-up includes blood pressure checks at subsequent visits.[2]
Differences from Standard Antidepressants
Unlike oral antidepressants (e.g., SSRIs), which patients take at home unsupervised, Spravato's rapid onset and side effect profile demand this setup. It's approved only for treatment-resistant depression or major depressive disorder with acute suicidal ideation, alongside an oral antidepressant.[1]
Who Can Administer It and Where
Only REMS-certified healthcare settings qualify, with trained providers. Over 1,000 sites are certified in the U.S. Janssen (Spravato's maker) provides a locator tool.[3]
Sources
[1]: FDA Spravato Label
[2]: Spravato REMS Program
[3]: Janssen Spravato HCP Site